Truist upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $35, up from $27. The firm notes that the company’s pharmacy shift is accelerating its revenue and profit growth, adding that the stock price underappreciates the upside, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
- Tandem Diabetes upgraded to Overweight from Neutral at Piper Sandler
- Tandem Diabetes Care Announces Convertible Senior Notes Offering
- Tandem Diabetes price target raised to $35 from $30 at BofA
- Closing Bell Movers: Keysight rallies 15% after earnings beat